Table I.
Clinicopathological characteristics of 62 patients with colorectal cancer.
| Clinicopathological characteristic | N (%)a |
|---|---|
| Age | |
| 30-59 years | 41 (66.13) |
| 60-89 years | 21 (33.87) |
| Site of cancer | |
| Colon | 54 (87.10) |
| Rectum | 8 (12.90) |
| Sex | |
| Male | 48 (77.42) |
| Female | 14 (22.58) |
| TNM stage | |
| I | 7 (11.29) |
| II | 6 (9.68) |
| III | 17 (27.42) |
| IV | 32 (51.61) |
| Treatment per TNM stage | |
| I | No chemotherapy; 6 (9.68) |
| Non-metastatic II, III and IV | XELIRI or XELOX; 45 (72.58) |
| Metastatic III and IV | XELIRI, XELOX and bevacizumab; 11 (17.74) |
| CEA per TNM stage (ng/ml) | |
| I | 2.86±0.48 |
| II | 5.89±4.26 |
| III | 8.44±3.58 |
| IV | 12.34±2.72 |
a
Data are presented as n (%) for age, site of cancer, sex and TNM stage, but as the mean ± SEM for CEA. TNM, cancer staging system; CEA, carcinoembryonic antigen.